Intuitive Surgical's Q3 da Vinci procedure growth market centers on the company's maintained full-year 2026 guidance of 13.5-15.5%, with results expected near the midpoint following Q2's 15% da Vinci increase. Moderation in U.S. growth to 12% in Q2, attributed to Affordable Care Act subsidy shifts and larger base effects, contrasts with robust 20% OUS expansion, while da Vinci 5 adoption supports higher utilization. Analysts project overall Q3 revenue near $2.88-2.91 billion ahead of the October 20 earnings release, with Q3 2025's 19% comp creating a tougher year-over-year comparison. These dynamics underpin the 45% implied probability on the 12.5-15% bucket as traders weigh recurring revenue resilience against potential sequential softening.